Hyperdense middle cerebral artery sign and outcome after intravenous thrombolysis for acute ischemic stroke

  • Aries M
  • Uyttenboogaart M
  • Koopman K
 et al. 
  • 1


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


BACKGROUND: The presence of a hyperdense middle cerebral artery sign (HMCAS) on baseline brain CT is associated with poor clinical outcome in stroke patients treated with intravenous recombinant tissue plasminogen activator (tPA). It remains uncertain whether the presence of HMCAS is associated with acute neurological deterioration after tPA treatment. OBJECTIVE: To evaluate the effect of HMCAS in routinely intravenous tPA-treated patients with anterior circulation stroke on acute neurological deterioration, the 3-month functional outcome and the occurrence of symptomatic ICH. METHODS: We analyzed data from a single stroke unit registry of 384 consecutive patients with anterior circulation infarction, treated with intravenous tPA. Logistic regression models were used to assess if HMCAS was independently associated with predefined outcome definitions. RESULTS: We found a HMCAS in 104 patients (27%). The HMCAS was related to the risk of early neurological deterioration (p=0.04) and poor functional outcome (p

Author-supplied keywords

  • *Brain Infarction/dt [Drug Therapy]
  • *Brain Infarction/ra [Radiography]
  • *Fibrinolytic Agents/tu [Therapeutic Use]
  • *Middle Cerebral Artery/ra [Radiography]
  • *Thrombolytic Therapy
  • *Tissue Plasminogen Activator/tu [Therapeutic Use]
  • 0 (Fibrinolytic Agents)
  • 0 (Recombinant Proteins)
  • Acute Disease
  • Aged
  • Brain Ischemia/dt [Drug Therapy]
  • Brain Ischemia/ra [Radiography]
  • Brain/de [Drug Effects]
  • Brain/ra [Radiography]
  • EC 3-4-21-68 (Tissue Plasminogen Activator)
  • Female
  • Fibrinolytic Agents/ad [Administration & Dosage]
  • Follow-Up Studies
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Cerebral Artery/de [Drug Effects]
  • Recombinant Proteins/ad [Administration & Dosage]
  • Recombinant Proteins/tu [Therapeutic Use]
  • Registries
  • Stroke/dt [Drug Therapy]
  • Stroke/ra [Radiography]
  • Time Factors
  • Tissue Plasminogen Activator/ad [Administration &
  • Tomography, X-Ray Computed
  • Treatment Outcome

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • M J Aries

  • M Uyttenboogaart

  • K Koopman

  • L A Rodiger

  • P C Vroomen

  • J De Keyser

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free